logo
Home  > Methanesulfonamide, N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]-

AA26931

123663-49-0 | Methanesulfonamide, N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]-

Packsize Purity Availability Price Discounted Price    Quantity
1mg 98% in stock $15.00 $10.00 -   +
5mg 98% in stock $18.00 $12.00 -   +
10mg 98% in stock $22.00 $15.00 -   +
50mg 98% in stock $26.00 $18.00 -   +
100mg 98% in stock $32.00 $22.00 -   +
250mg 98% in stock $42.00 $29.00 -   +
1g 98% in stock $99.00 $69.00 -   +
5g 98% in stock $419.00 $293.00 -   +
25g 98% in stock $2,042.00 $1,429.00 -   +

*All products are for research use only and not intended for human or animal use.

*All prices are in USD.

Request Bulk Quote
Description
Catalog Number: AA26931
Chemical Name: Methanesulfonamide, N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]-
CAS Number: 123663-49-0
Molecular Formula: C17H14N2O6S
Molecular Weight: 374.3679
MDL Number: MFCD00882374
SMILES: O=CNc1coc2c(c1=O)cc(c(c2)NS(=O)(=O)C)Oc1ccccc1

 

Computed Properties
Complexity: 665  
Covalently-Bonded Unit Count: 1  
Heavy Atom Count: 26  
Hydrogen Bond Acceptor Count: 7  
Hydrogen Bond Donor Count: 2  
Rotatable Bond Count: 5  
XLogP3: 1.4  

 

 

Upstream Synthesis Route 
  • Iguratimod, also known by its brand name T-614, is a synthetic disease-modifying anti-rheumatic drug (DMARD) that has shown promising applications in chemical synthesis. In the field of chemistry, Iguratimod is particularly valued for its ability to inhibit the production of inflammatory cytokines such as TNF-α, IL-1β, and IL-6. This unique property of Iguratimod makes it an attractive candidate for use in the development of novel pharmaceuticals and chemical compounds with anti-inflammatory and immunomodulatory properties. By incorporating Iguratimod into chemical synthesis processes, researchers can explore its potential in creating new drug candidates that target autoimmune diseases, inflammatory conditions, and other related disorders. Additionally, Iguratimod's mechanism of action as a DMARD opens up avenues for its utilization in designing molecules with enhanced therapeutic effects and reduced side effects, ultimately contributing to the advancement of drug discovery and development.
Literature
FEATURED PRODUCTS